| Expression pattern: |
DN |
| Associated gene: |
Hippo-YAP pathway, RSU1, STAG2 |
| Associated microRNA: |
hsa-miR-1277, hsa-miR-331-5p, hsa-miR-409-3p, hsa-miR-515-5p, hsa-miR-1276 |
| Biological function: |
Lower expression is associated with advanced pT stage and lymph node metastasis (pN stage); potential progression biomarker. |
| Molecular mechanism: |
Predicted to act as a miRNA sponge (ceRNA-like). |
| Biological pathway or process: |
metastasis (inhibits); invasion (inhibits); EMT (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RNase R Treatment; RT-qPCR; divergent primers PCR; Sanger Sequencing; Clinical Sample Validation; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
Low expression correlates with advanced pT stage and lymph node metastasis; AUC for pN stage reported as 0.8209. |
| Description: |
hsa_circ_0072309 (chr5:38523418-38530666-, host gene LIFR) is down-regulated in PTC. Lower expression is linked to advanced pT stage and lymph node metastasis, suggesting a suppressive association with progression and potential as a progression biomarker; it is predicted to bind miR-409-3p and other miRNAs. |
| Confidence score: |
0.6841 |